Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Double-Dummy, Prospective, Randomized Multiple-Site Study of Oral Finafloxacin 300 mg b.i.d. Versus Oral Ciprofloxacin 250 mg b.i.d. in Patients With Lower Uncomplicated UTI (uUTI) With a Treatment Duration of 3 Days.

Next Previous
Trial Profile

A Double-Blind, Double-Dummy, Prospective, Randomized Multiple-Site Study of Oral Finafloxacin 300 mg b.i.d. Versus Oral Ciprofloxacin 250 mg b.i.d. in Patients With Lower Uncomplicated UTI (uUTI) With a Treatment Duration of 3 Days.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jan 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Finafloxacin (Primary) ; Ciprofloxacin
  • Indications Bacterial infections; Urinary tract infections
  • Focus Proof of concept; Therapeutic Use
  • Acronyms FLUT

Most Recent Events

  • 16 Jan 2018 Results of pooled data from two trials (NCT01928433 and NCT00722735) assessing the clinical efficacy and antibacterial activity of finafloxacin compared with ciprofloxacin in the treatment of uUTI and cUTI/PN, were published in the Antimicrobial Agents and Chemotherapy.
  • 21 Sep 2015 Pooled analysis results from this trial and an another trial presented at the Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy
  • 30 Apr 2012 Planned number of patients changed from 36 to 48 as reported by European Clinical Trials Database.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top